Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2023-09-21
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multimodal PET Imaging With 18F-FDG/SV2A/TSPO for Resection Planning in Drug-Resistant Epilepsy
NCT07147309
Mapping Epileptic Networks Using Multimodal Imaging
NCT06202976
Study of Metabolic Connectivity in Drug-resistant Temporal Epilepsy
NCT05455047
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
NCT02107989
Multimodal Imaging in Pre-surgical Evaluation of Epilepsy
NCT01735032
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Controls
Healthy control subjects with no major medical history
FDG-PET/fMRI/EEG imaging
Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.
Subjects with Epilepsy
Subjects diagnosed with epilepsy and with abnormal electrical activity recorded on interictal EEG.
FDG-PET/fMRI/EEG imaging
Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FDG-PET/fMRI/EEG imaging
Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with epilepsy with abnormal interictal EEG
Exclusion Criteria
* History of severe brain disease such as stroke and head trauma
* History of brain surgery
* History of type I or II diabetes mellitus
* Fasting plasma glucose level \>200 mg/dL
* Employed under direct supervision of the PI conducting the research
* Current use of drugs that modulate brain function
* Current or past history of major medical, neurological, or psychiatric conditions
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ciprian Catana, MD, PhD
Professor of Radiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ciprian Catana, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Athinoula A. Martinos Center
Charlestown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ciprian Catana
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022P000929
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.